This inventor holds 2 USPTO granted patents and 2 published patent applications and 11 EPO patents. Top assignees: Evotec Ag, Takeda Pharmaceutical Company Limited. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2013
Title: Heinz Von Der Kammer: Innovator in Neurodegenerative Disease Research
Introduction
Heinz Von Der Kammer is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patented inventions. With a total of 2 patents, his work focuses on understanding and addressing conditions such as Alzheimer's disease.
Latest Patents
His latest patents include "PPM1E proteins and nucleic acids as targets for neurodegenerative diseases" and "Use of Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases." The latter patent discloses a dysregulation of a PRKX gene and its protein products in Alzheimer's disease patients and individuals at risk of developing the disease. This invention provides methods for diagnosing and prognosticating Alzheimer's disease, as well as therapeutic and prophylactic methods for treatment and prevention. Additionally, it includes screening methods for modulating agents related to neurodegenerative diseases.
Career Highlights
Heinz has worked with prominent companies in the pharmaceutical and biotechnology sectors, including Evotec AG and Takeda Pharmaceutical Company Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Heinz has collaborated with notable coworkers such as Johannes Pohlner and Thomas Hesterkamp. Their combined expertise has further advanced the understanding of neurodegenerative diseases and the development of innovative solutions.
Conclusion
Heinz Von Der Kammer's contributions to neurodegenerative disease research through his patents and collaborations highlight his commitment to improving diagnostic and therapeutic methods. His work continues to pave the way for advancements in the field, ultimately benefiting patients and the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile